Bioverativ Inc (BIVV) Shares Bought by APG Asset Management N.V.
APG Asset Management N.V. raised its holdings in shares of Bioverativ Inc (NASDAQ:BIVV) by 1,360.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 780,100 shares of the biotechnology company’s stock after buying an additional 726,700 shares during the quarter. APG Asset Management N.V.’s holdings in Bioverativ were worth $35,029,000 as of its most recent SEC filing.
Several other hedge funds have also modified their holdings of the company. SG Americas Securities LLC lifted its holdings in shares of Bioverativ by 472.6% during the fourth quarter. SG Americas Securities LLC now owns 32,850 shares of the biotechnology company’s stock worth $1,771,000 after buying an additional 27,113 shares during the last quarter. Hendershot Investments Inc. lifted its holdings in shares of Bioverativ by 4.8% during the fourth quarter. Hendershot Investments Inc. now owns 17,662 shares of the biotechnology company’s stock worth $952,000 after buying an additional 807 shares during the last quarter. State of Alaska Department of Revenue acquired a new position in shares of Bioverativ during the fourth quarter worth approximately $428,000. Acadian Asset Management LLC raised its stake in shares of Bioverativ by 54.7% in the fourth quarter. Acadian Asset Management LLC now owns 1,246,815 shares of the biotechnology company’s stock valued at $67,229,000 after purchasing an additional 441,084 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. raised its stake in shares of Bioverativ by 8.8% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 343,731 shares of the biotechnology company’s stock valued at $18,534,000 after purchasing an additional 27,800 shares in the last quarter. Institutional investors own 96.04% of the company’s stock.
Bioverativ Inc (NASDAQ:BIVV) opened at $103.03 on Monday. Bioverativ Inc has a 12 month low of $41.88 and a 12 month high of $104.30. The stock has a market capitalization of $11,150.00 and a price-to-earnings ratio of 25.19.
BIVV has been the subject of a number of recent research reports. Jefferies Group upped their target price on Bioverativ to $79.00 and gave the company a “buy” rating in a research note on Thursday, January 18th. Zacks Investment Research upgraded Bioverativ from a “hold” rating to a “buy” rating and set a $62.00 target price for the company in a research note on Monday, January 8th. Morgan Stanley upgraded Bioverativ from an “underweight” rating to an “equal weight” rating in a research note on Tuesday, January 23rd. Deutsche Bank set a $53.00 target price on Bioverativ and gave the company a “hold” rating in a research note on Monday, November 20th. Finally, Raymond James Financial lowered Bioverativ from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 23rd. Thirteen equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $62.53.
COPYRIGHT VIOLATION NOTICE: “Bioverativ Inc (BIVV) Shares Bought by APG Asset Management N.V.” was published by Daily Political and is the property of of Daily Political. If you are accessing this story on another website, it was illegally stolen and republished in violation of US & international copyright and trademark law. The correct version of this story can be read at https://www.dailypolitical.com/2018/01/29/bioverativ-inc-bivv-shares-bought-by-apg-asset-management-n-v.html.
Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.
Want to see what other hedge funds are holding BIVV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bioverativ Inc (NASDAQ:BIVV).
Receive News & Ratings for Bioverativ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ and related companies with MarketBeat.com's FREE daily email newsletter.